The whole architecture of generic-drug litigation starts with a choice among four certifications. When a company files an Abbreviated New Drug Application — an ANDA, the pathway for a generic copy of an approved drug — it must address every patent the brand has listed for that drug. 21 U.S.C. 355(j)(2)(A)(vii) gives the applicant exactly four options for each patent: (i) that no such patent information has been filed, (ii) that the patent has expired, (iii) the date on which the patent will expire, or (iv) that the patent is invalid or will not be infringed. The fourth option is the Paragraph IV certification, and it is the only one that says, in effect, the generic intends to come to market before the patent's natural expiry because it contends the patent does not block it.

The statute states the Paragraph IV option in plain terms: the applicant certifies “that such patent is invalid or will not be infringed by the manufacture, use, or sale of the new drug for which the application is submitted.” That single sentence carries enormous procedural weight. A certification under (i), (ii), or (iii) raises no immediate patent dispute — the generic is simply waiting out or around the patent. A Paragraph IV certification is an affirmative legal position against an in-force patent, and the Hatch-Waxman scheme treats the very act of filing it as the event that opens the door to litigation.

"...(iv) that such patent is invalid or will not be infringed by the manufacture, use, or sale of the new drug for which the application is submitted."— 21 U.S.C. 355(j)(2)(A)(vii), source

How does a Paragraph IV ANDA challenge work step by step?

After filing a Paragraph IV certification, the applicant must give notice to the patent owner and the holder of the reference application, explaining the factual and legal basis for its contention that each patent is invalid or not infringed. That notice starts a clock. The patent owner has a defined window — 45 days — to sue for infringement. Under the statute, the mere act of submitting an ANDA with a Paragraph IV certification is itself treated as an act of infringement, which is what gives the patent owner a basis to sue before the generic has sold a single dose. This is the doctrine that makes Hatch-Waxman litigation possible at the application stage rather than only after a launch.

If the patent owner sues within the 45-day window, the FDA is generally barred from approving the ANDA for 30 months while the dispute proceeds, unless the court resolves the patent question sooner. That 30-month stay is the central leverage point of the system: it pauses generic approval without requiring the patent owner to prove anything yet, while the validity and infringement questions are litigated. If the patent owner does not sue within the window, the stay does not attach and FDA review can continue. The outcome of the suit — a finding of invalidity, non-infringement, or infringement — then determines whether and when the generic can enter.

The 30-month stay is worth pinning down precisely, because it is frequently described loosely. The stay is not a finding that the patent is valid or infringed; it is a statutory pause that attaches automatically when the patent owner sues within the 45-day window, holding off final FDA approval while the court works through the patent questions. It runs for 30 months from the patent owner's receipt of the Paragraph IV notice, but it can end early — if the court rules for the generic on validity or infringement, or otherwise resolves the case, the stay lifts. The stay can also be shortened or extended by the court in defined circumstances. The point is that the stay is a function of the procedural posture, not of the merits, and a generic that prevails in the litigation is not blocked by the stay's nominal length.

Why the first filer matters

The Hatch-Waxman framework also rewards being first. The first applicant to file a substantially complete ANDA with a Paragraph IV certification can be eligible for a period of marketing exclusivity — 180 days — during which the FDA will not approve a later generic for the same drug. That incentive is why Paragraph IV filings are often raced to be first and why a single listed patent can attract multiple challengers. The exclusivity is a creature of the same statute and is tied to the Paragraph IV mechanism, not to winning the litigation outright.

For an IP-litigation reader, the takeaway is procedural precision: a Paragraph IV certification is not a lawsuit, and it is not a ruling. It is a statutory statement — invalid or not infringed — whose filing is treated as an act of infringement, sets a 45-day suit window, and can produce a 30-month stay. Each of those is a defined step in 21 U.S.C. 355(j), and conflating the certification with a holding on the merits misreads where in the process a given matter actually stands.

One further nuance ties the Paragraph IV mechanism back to the patents themselves. The certifications respond to patents the brand has listed in the FDA's publication of approved drug products — the Orange Book — for the reference drug. Which patents are listed, and whether they are properly listed, can itself become contested, because a Paragraph IV challenger must address every listed patent and the scope of those patents defines the battlefield. A listed patent claiming the active ingredient invites a different challenge than one claiming a formulation or a method of use, and a generic may certify Paragraph IV as to some listed patents while making a different certification as to others. Reading an ANDA dispute accurately means knowing not just that a Paragraph IV certification was filed, but which listed patents it targets and on what ground — invalidity, non-infringement, or both.

This article describes the statutory mechanism; it is not legal advice, and the posture of any specific ANDA matter depends on the certifications filed, the suits brought, and the court's rulings on the record.